Libbs was established in 1958 and is headquartered in the city of Sao Paulo, Brazil and is a major player in the Brazilian pharmaceutical market. The company is privately owned and produces and commercializes prescription drugs to the ethical market. Libbs also produces, sells and exports raw materials and active pharmaceutical ingredients (APIs) and in- licenses and out-licenses products. Total revenues in 2007 reached to US$220 million overall, with 2.3% market share (IMS). The company's key areas are:

• CNS

• Dermatology

• GI

• Respiratory/pediatrics

• Cardiology

• Gynecology, Contraception, HRT

• Oncology.

Libbs is a financially sound company that has consistently invested in new resources. Our new manufacturing site which is now fully operational houses all our production lines, including hormones and cytostatic drugs.

Our new facilities will benefit from having its pharmaceutical production alongside the API production plant. Special attention is being given to the new research and development center where a body of medical researchers works hand-in-hand with academics offering the scientific support needed in the development of new products and new drug delivery systems.

We offer:

• One of the biggest sales force in the Brazilian market with 600 medical reps;
• Strong development structure and capability with success records in bioequivalence studies approval;
• State-of-the-art manufacturing facility (new)
• Export of API's as well as Finished Formulations

We are interested in:

• In-licensing
• Co-development (late stages)
• Co-marketing, Co-promotion, Fostering
• Supply agreements, import and export of API's as well as FF
• Technology transfer

Therapeutical areas:

• Cardiovascular (Hypertension, Metabolic syndrome, Diabetes, Coagulation, Arrhythmias)
• Gynecology (Contraception, HRT)
• Central Nervous System (Depression, Parkinson, Alzheimer, Sleep disorders)
• Dermatology (Dermatitis, Psoriasis,)
• Oncology
• Respiratory diseases (Asthma, DPOC, Rhinitis)

Main features of development interest:

• Modified release, Drug Delivery
• Late stage clinical development or regulatory approval stage
• Strong Medical Evidence, value-added, patent or innovation barrier
• Oncology and Biotechnology

Export of API's

• Amiodarone HCl, Bromopride, Cilostazol, Gestodene, Desogestrel, Mazindol, Paroxetine HCl, Tibolone